Peran BST-2 (Bone Marrow Stromal Antigen-2) terhadap Infeksi HIV
DOI:
https://doi.org/10.54639/mhj.v7i2.1610Abstract
Infeksi Human Immunodeficiency Virus (HIV) merupakan masalah kesehatan global yang menyebabkan melemahnya sistem imun dan berkembang menjadi Acquired Immunodeficiency Syndrome (AIDS). Dalam merespons infeksi HIV, tubuh manusia mengaktifkan berbagai faktor pertahanan intraseluler, salah satunya adalah Bone Marrow Stromal Antigen 2 (BST-2), yang juga dikenal sebagai tetherin, CD317, atau HM1.24. BST-2 merupakan protein transmembran yang berfungsi sebagai faktor restriksi host terhadap virus envelop, termasuk HIV. Artikel ini merupakan kajian literatur yang bertujuan untuk menelaah secara mendalam peran BST-2 terhadap infeksi HIV. Hasil telaah dari tujuh artikel penelitian eksperimen menunjukkan bahwa BST-2 memiliki peran penting dalam menghambat pelepasan virion HIV dari sel inang, menurunkan infektivitas HIV, mencegah penyebaran HIV secara langsung antar sel, aktivasi antibody-dependent cellular cytotoxicity (ADCC), dan aktivasi respon inflamasi.
References
Akollo IR. Ilmu Dasar Keperawatan: Virologi dan Bakteriologi [Internet]. 1st ed. Depok: Rajawali Pers; 2023 [cited 2025 Apr 6]. Available from: https://www.rajagrafindo.co.id/produk/ilmu-dasar-keperawatan-virologi-dan-bakteriologi-isak-roberth-akollo-s-kep-m-sc/
Dembelu M, Woseneleh T. Prevalence of and factors associated with reoccurrence of opportunistic infections among adult hiv/aids patients attending the art clinic at public health facilities in arba minch town, southern Ethiopia. HIV/AIDS - Research and Palliative Care. 2021;13(July):867–76.
Presle A, Frémont S, Salles A, Commere PH, Sassoon N, Berlioz-Torrent C, et al. The viral restriction factor tetherin/BST2 tethers cytokinetic midbody remnants to the cell surface. Current Biology. 2021 May 24;31(10):2203-2213.e5.
Rossi E, Meuser ME, Cunanan CJ, Cocklin S. Structure, function, and interactions of the hiv-1 capsid protein. Life. 2021 Feb 1;11(2):1–25.
Bbosa N, Kaleebu P, Ssemwanga D. HIV subtype diversity worldwide. Vol. 14, Current Opinion in HIV and AIDS. Lippincott Williams and Wilkins; 2019. p. 153–60.
Reuschl AK, Mesner D, Shivkumar M, Whelan MVX, Pallett LJ, Guerra-Assunção JA, et al. HIV-1 Vpr drives a tissue residency-like phenotype during selective infection of resting memory T cells. Cell Rep. 2022 Apr 12;39(2).
Woottum M, Yan S, Durringer A, Mézière L, Bracq L, Han M, et al. HIV-1 cell-to-cell infection of macrophages escapes type I interferon and host restriction factors, and is resistant to antiretroviral drugs. PLoS Pathog. 2025 Apr 1;21(4 April).
Yu H, Bian Q, Wang X, Wang X, Lai L, Wu Z, et al. Bone marrow stromal cell antigen 2: Tumor biology, signaling pathway and therapeutic targeting (Review). Oncol Rep. 2024 Mar 1;51(3).
Shi Y, Simpson S, Chen Y, Aull H, Benjamin J, Serra-Moreno R. Mutations accumulated in the Spike of SARSCoV-2 Omicron allow for more efficient counteraction of the restriction factor BST2/Tetherin. PLoS Pathog. 2024 Jan 1;20(1).
Dias BDC, Paximadis M, Martinson N, Chaisson RE, Ebrahim O, Tiemessen CT. The impact of bone marrow stromal antigen-2 (BST2) gene variants on HIV-1 control in black South African individuals. Infection, Genetics and Evolution. 2020 Jun 1;80.
Park S, Yi E, Jeon J, Oh J, Xu Z, Park SH. The Role of Bone Marrow Stromal Cell Antigen 2 (BST2) in the Migration of Dendritic Cells to Lymph Nodes. Int J Mol Sci. 2025 Jan 1;26(1).
Shan F, Shen S, Wang X, Chen G. BST2 regulated by the transcription factor STAT1 can promote metastasis, invasion and proliferation of oral squamous cell carcinoma via the AKT/ERK1/2 signaling pathway. Int J Oncol. 2023 Apr 1;62(4).
Zhang M Di, Chen F, He WQ, Lu Y, Liu FL, Zhang HG, et al. The Deubiquitinase OTUD1 Influences HIV-1 Release by Regulating the Host Restriction Factor BST-2. Viruses. 2025 Feb 1;17(2).
Olety B, Peters P, Wu Y, Usami Y, Göttlinger H. HIV-1 propagation is highly dependent on basal levels of the restriction factor BST2. Sci Adv [Internet]. 2021;7. Available from: https://www.science.org
Mahauad-Fernandez WD, Okeoma CM. The role of BST-2/Tetherin in host protection and disease manifestation. Vol. 4, Immunity, Inflammation and Disease. Wiley-Blackwell; 2016. p. 4–23.
Tiwari R, De La Torre JC, Mcgavern DB, Nayak D. Beyond Tethering the Viral Particles: Immunomodulatory Functions of Tetherin (BST-2). DNA Cell Biol. 2019 Nov 1;38(11):1170–7.
Singh R, Ramsuran V, Naranbhai V, Yende-Zuma N, Garrett N, Mlisana K, et al. Epigenetic Regulation of BST-2 Expression Levels and the Effect on HIV-1 Pathogenesis. Front Immunol. 2021 May 5;12.
Giese S, Lawrence SP, Mazzon M, Nijmeijer BM, Marsh M. The nef protein of the macrophage tropic HIV-1 strain AD8 counteracts human BST-2/tetherin. Viruses. 2020 Apr 1;12(4).
Mlimi H, Naidoo KK, Mabuka J, Ndung’u T, Madlala P. Bone marrow stromal antigen 2 (BST-2) genetic variants influence expression levels and disease outcome in HIV-1 chronically infected patients. Retrovirology. 2022 Dec 1;19(1).
Zheng C, Wang J, Zhou Y, Duan Y, Zheng R, Xie Y, et al. IFN?-induced BST2+ tumor-associated macrophages facilitate immunosuppression and tumor growth in pancreatic cancer by ERK-CXCL7 signaling. Cell Rep. 2024 Apr 23;43(4).
Temerozo JR, Ferreira PLC, Linhares-Lacerda L, Vieira RC, Cister-Alves B, Gobbo L, et al. Interleukin-27 Promotes Divergent Effects on HIV-1 Infection in Peripheral Blood Mononuclear Cells through BST-2/Tetherin. J Virol. 2023 Jan 31;97(1).
Li K, Zhou Z, Liu F, Huang Z, Chen X, Zhou F. Unphosphorylated STAT1 binds to the BST2 transcription promoter, promoting increased AKBA anchoring on HPMECs to alleviate ARDS. Sci Rep. 2025 Dec 1;15(1).
Casartelli N, Sourisseau M, Feldmann J, Guivel-Benhassine F, Mallet A, Marcelin AG, et al. Tetherin restricts productive HIV-1 cell-to-cell transmission. PLoS Pathog. 2010 Jun;6(6).
Kuhl BD, Sloan RD, Donahue DA, Bar-Magen T, Liang C, Wainberg MA. Tetherin restricts direct cell-to-cell infection of HIV-1. Retrovirology. 2010 Dec 24;7.
Zhang J, Liang C. BST-2 Diminishes HIV-1 Infectivity. J Virol. 2010 Dec;84(23):12336–43.
Pham TNQ, Lukhele S, Dallaire F, Perron G, Cohen ÉA. Enhancing Virion Tethering by BST2 Sensitizes Productively and Latently HIV-infected T cells to ADCC Mediated by Broadly Neutralizing Antibodies. Sci Rep. 2016 Nov 17;6.
Richard J, Prévost J, von Bredow B, Ding S, Brassard N, Medjahed H, et al. BST-2 Expression Modulates Small CD4-Mimetic Sensitization of HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity. 2017; Available from: https://doi.org/10.1128/JVI
Galão RP, Le Tortorec A, Pickering S, Kueck T, Neil SJD. Innate sensing of HIV-1 assembly by tetherin induces NF?B-dependent proinflammatory responses. Cell Host Microbe. 2012 Nov 15;12(5):633–44.
Berry KN, Kober DL, Su A, Brett TJ. Limiting Respiratory Viral Infection by Targeting Antiviral and Immunological Functions of BST-2/Tetherin: Knowledge and Gaps. BioEssays. 2018 Oct 1;40(10).
Li SX, Barrett BS, Guo K, Kassiotis G, Hasenkrug KJ, Dittmer U, et al. Tetherin/BST-2 promotes dendritic cell activation and function during acute retrovirus infection. Sci Rep. 2016 Feb 5;6.
Evans DT, Serra-Moreno R, Singh RK, Guatelli JC. BST-2/tetherin: A new component of the innate immune response to enveloped viruses. Vol. 18, Trends in Microbiology. 2010. p. 388–96.
Zhao Y, Zhao K, Wang S, Du J. Multi-functional BST2/tetherin against HIV-1, other viruses and LINE-1. Front Cell Infect Microbiol. 2022 Sep 13;12.
Tokarev A, Suarez M, Kwan W, Fitzpatrick K, Singh R, Guatelli J. Stimulation of NF-?B Activity by the HIV Restriction Factor BST2. J Virol. 2013 Feb 15;87(4):2046–57.
Downloads
Published
Issue
Section
License
Hak cipta
Penulis memegang hak cipta dan memberikan Moluccas Health Journal: Jurnal Kesehatan (MHJ) hak penerbitan pertama dengan karya yang dilisensikan secara simultan di bawah Atribusi Internasional 4.0 (CC BY 4.0) yang memungkinkan orang lain untuk mencampur, mengadaptasi, dan mengembangkan karya tersebut dengan pengakuan atas kepengarangan karya dan publikasi awal di Moluccas Health Journal: Jurnal Kesehatan (MHJ).
Penulis diperkenankan untuk menyalin dan mendistribusikan ulang versi jurnal yang diterbitkan (misalnya, mempostingnya ke repositori institusi atau menerbitkannya dalam sebuah buku), dengan mencantumkan pengakuan penerbitan awal di Moluccas Health Journal: Jurnal Kesehatan (MHJ)
Lisensi
Artikel yang diterbitkan dalam Moluccas Health Journal: Jurnal Kesehatan (MHJ) dilisensikan di bawah lisensi Atribusi 4.0 Internasional (CC BY 4.0). Anda bebas untuk:
Bagikan, salin dan distribusikan ulang materi dalam media atau format apa pun.
Beradaptasi, mencampur, mengubah, dan mengembangkan materi tersebut untuk tujuan apa pun, bahkan secara komersial.
Lisensi ini dapat diterima untuk Karya Budaya Bebas. Pemberi lisensi tidak dapat mencabut kebebasan ini selama Anda mematuhi ketentuan lisensi. Berdasarkan ketentuan berikut:
Atribusi: Anda harus memberikan penghargaan yang sesuai, menyediakan tautan ke lisensi, dan menunjukkan jika ada perubahan yang dilakukan. Anda dapat melakukannya dengan cara yang wajar, tetapi tidak dengan cara yang menunjukkan bahwa pemberi lisensi mendukung Anda atau penggunaan Anda.
Tidak ada batasan tambahan: Anda tidak boleh menerapkan ketentuan hukum atau tindakan teknologi yang secara hukum membatasi orang lain untuk melakukan apa pun yang diizinkan oleh lisensi.
